Search results
Results From The WOW.Com Content Network
The guide has been published annually since 1986 with the World Health Organization becoming involved in 2000, [2] [3] though has not been updated since 2015. [4] The prices in the guide are specifically for low and middle income countries (LMIC). [2] There are two sources of price data in the guide: Buyers and Suppliers.
Ranbaxy's Malvinder Singh remained as CEO after the transaction. [11] The addition of Ranbaxy Laboratories extended Daiichi-Sankyo's operations, with the combined company worth about US$30 billion. [12] In 2009, it was reported that former Novartis Senior Vice-President Yugal Sikri would lead the Indian operations of Ranbaxy Laboratories. [13] [14]
The price of a new drug (in most cases) is limited so that the cost of therapy with the new drug is in the range of the costs of therapy with existing drugs in the same therapeutic class. The price of a breakthrough drug is limited to the median of its prices in France, Germany, Italy, Sweden, Switzerland, Britain, and the United States.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Volini is a brand of pain relief medical spray and cream manufactured, marketed and sold by Sun Pharma in India. [1] [2] The product was created by Ranbaxy Laboratories, but has been owned by Sun Pharma ever since Ranbaxy was acquired by the latter in 2014. [3]
On June 10, 2008, the company agreed to take a majority (64%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion. [13] [14] It acquired U3 Pharma in June 2008, contributing a therapeutic anti-HER3 antibody to the company's anticancer portfolio. [15] The company closed U3 Pharma in 2015. [16]
In 2006, Advent had sold 96.7% of the company to Ranbaxy. Terapia S.A. therefore went through a brand name change, and so it became Terapia Ranbaxy. Two years later, the Japanese pharmaceutical giant Daiichi Sankyo had purchased 1/5 of the company, and so Terapia Ranbaxy became part of the giant.
From Wikipedia, the free encyclopedia. Redirect page